Research
Merck: The Beat Is Real — the Bridge Is the Argument
Revenue $18,085M, +4.35% vs estimate and +5.25% YoY on the filed September quarter · non-GAAP EPS $2.49 vs $2.09 (+19.14%) · Keytruda family $8.6B (+6%) with QLEX at $830M — and the close was +3.83% to $146.33 Merck & Co., Inc. (MRK, NYSE)